DK2484696T3 - Antagonistiske hLIGHT-specifikke humane monoklonale antistoffer - Google Patents

Antagonistiske hLIGHT-specifikke humane monoklonale antistoffer Download PDF

Info

Publication number
DK2484696T3
DK2484696T3 DK12162958.8T DK12162958T DK2484696T3 DK 2484696 T3 DK2484696 T3 DK 2484696T3 DK 12162958 T DK12162958 T DK 12162958T DK 2484696 T3 DK2484696 T3 DK 2484696T3
Authority
DK
Denmark
Prior art keywords
antibody
hlight
pta
seq
nos
Prior art date
Application number
DK12162958.8T
Other languages
English (en)
Inventor
Steven W Granger
Shinichiro Kato
Carl F Ware
Original Assignee
Kyowa Hakko Kirin Co Ltd
Lajolla Inst For Allergy And Immunology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39126775&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK2484696(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Kyowa Hakko Kirin Co Ltd, Lajolla Inst For Allergy And Immunology filed Critical Kyowa Hakko Kirin Co Ltd
Application granted granted Critical
Publication of DK2484696T3 publication Critical patent/DK2484696T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Wood Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Analytical Chemistry (AREA)
  • Plant Pathology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Food Science & Technology (AREA)
  • Transplantation (AREA)

Claims (21)

1. Isoleret antistof eller et hLIGHT-bindingsfragment deraf, hvor antistoffet og fragmentet deraf binder sig til den trimere men ikke til den monomere form af hLIGHT, hvor binding til hLIGHT-epitopen fra antistoffets og fragmentets side blokeres kompetitivt af et antistof dannet af hybridomet med ATCC-tilgangsnummer PTA-7819, og hvor bindingen ikke blokeres kompetitivt af antistofferne dannet af hybridomerne med ATCC-tilgangsnumrene PTA-7729, PTA-7842 og PTA-7818, hvor antistoffet og fragmentet hæmmer binding af HVEM og LTpR til hLIGHT, og hvor antistoffet og fragmentet binder sig til enkeltnukleotidpolymor-fisme(SNP)hLIGHT-varianterne 214E-32S og 214K-32S, 214E-32L og 214K-32L, hvor antistoffet er et antagonistantistof.
2. Antistof eller hLIGHT-bindingsfragment deraf ifølge krav 1, hvor binding til hLIGHT-epitopen fra antistoffets og fragmentets side blokeres kompetitivt af et antistof dannet af hybridomet med ATCC-tilgangsnummer PTA-7728.
3. Antistof eller hLIGHT-bindingsfragment deraf ifølge krav 1 eller krav 2, hvor antistoffet konkurrerer med HVEM, LTPR eller et fusionsprotein deraf om binding til celleoverfla-deudtrykt hLIGHT eller opløselig hLIGHT.
4. Antistof eller hLIGHT-bindingsfragment deraf ifølge et hvilket som helst af kravene 1 til 3, hvor antistoffet omfatter: et VH-domæne med aminosyresekvensen fra rest 27 til rest 143 i SEQ ID NO: 5 og et VL-domæne med aminosyresekvensen fra rest 23 til rest 129 i SEQ ID NO: 10.
5. Antistof eller hLIGHT-bindingsfragment deraf ifølge et hvilket som helst af kravene 1 til 3, hvor antistoffet omfatter: (a) en variabel tungkæderegion omfattende VH CDR1 med aminosyresekvensen ifølge SEQ ID NO:23, en VH CDR2 med aminosyresekvensen ifølge SEQ ID NO:24 og en VH CDR3 med aminosyresekvensen ifølge SEQ ID NO:25; og (b) en variabel letkæderegion omfattende VL CDR1 med aminosyresekvensen ifølge SEQ ID NO:38, en VL CDR2 med aminosyresekvensen ifølge SEQ ID NO:39 og en VL CDR3 med aminosyresekvensen ifølge SEQ ID NO:40.
6. Antistof eller hLIGHT-bindingsfragment deraf ifølge et hvilket som helst af kravene 1 til 3, hvor antistoffet omfatter en VH og en VL af et antistof dannet af et hybridom med ATCC-tilgangsnummer PTA-7728.
7. Antistof eller hLIGHT-bindingsfragment deraf ifølge et hvilket som helst af kravene 1 til 3, hvor antistoffet omfatter (a) en VH CDR1, VH CDR2 og VH CDR3 og (b) en VL CDR1, VL CDR2 og VL CDR3 af et antistof dannet af et hybridom med ATCC-tilgangsnummer PTA-7728.
8. Antistof eller hLIGHT-bindingsfragment deraf ifølge krav 1, hvor antistoffet dannes af et hybridom med ATCC-tilgangsnummer PTA-7728.
9. Antistof eller hLIGHT-bindingsfragment deraf ifølge et hvilket som helst af kravene 1 til 8, hvor antistoffet er et fuldstændigt humant antistof, et kimært antistof eller et humaniseret antistof.
10. Antistof eller hLIGHT-bindingsfragment deraf ifølge et hvilket som helst af kravene 1 til 9, hvor antistoffet er et monoklonalt antistof.
11. Antistof eller hLIGHT-bindingsfragment deraf ifølge et hvilket som helst af kravene 1 til 10, hvor antistoffet er et rekombinant antistof.
12. hLIGHT-bindingsfragmentet ifølge et hvilket som helst af kravene 1 til 11, hvor fragmentet er et Fab-fragment, F(ab')2-fragment, enkeltkæde-Fv (scFv), diaantistof, triaan-tistof eller miniantistof.
13. Sammensætning omfattende antistoffet eller hLIGHT-bindingsfragmentet deraf ifølge et hvilket som helst af kravene 1 til 12.
14. Isoleret nukleinsyremolekyle kodende for antistoffet eller hLIGHT-bindingsfragmentet deraf ifølge et hvilket som helst af kravene 1 til 12.
15. Vektor, som omfatter nukleinsyremolekylet ifølge krav 14.
16. Værtscelle, som omfatter vektoren ifølge krav 15.
17. Fremgangsmåde til frembringelse af antistoffet eller hLIGHT-bindingsfragmentet deraf ifølge et hvilket som helst af kravene 1-12, hvilken fremgangsmåde omfatter; at dyrke værtscellen ifølge krav 16, at udtrykke antistoffet eller hLIGHT-bindingsfragmentet deraf, og at indvinde antistoffet eller hLIGHT-bindingsfragmentet deraf.
18. Hybridom, der danner antistoffet ifølge et hvilket som helst af kravene 1 til 8.
19. Hybridom ifølge krav 18, som danner antistoffet ifølge et hvilket som helst af kravene 1 eller 3 til 12, hvor hybridomet har ATCC-tilgangsnummeret PTA-7728 (124 F23).
20. Farmaceutisk sammensætning indeholdende antistoffet eller hLIGHT-bindingsfragmentet deraf ifølge et hvilket som helst af kravene 1 til 12 i et farmaceutisk acceptabelt bærestof.
21. Sæt, som omfatter antistoffet eller hLIGHT-bindingsfragmentet deraf ifølge et hvilket som helst af kravene 1 til 12, eller et sæt, som omfatter sammensætningen ifølge krav 13.
DK12162958.8T 2006-08-28 2007-08-24 Antagonistiske hLIGHT-specifikke humane monoklonale antistoffer DK2484696T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US84077406P 2006-08-28 2006-08-28
US89787507P 2007-01-25 2007-01-25
EP10172151.2A EP2292663B1 (en) 2006-08-28 2007-08-24 Antagonistic human light-specific human monoclonal antibodies

Publications (1)

Publication Number Publication Date
DK2484696T3 true DK2484696T3 (da) 2017-10-02

Family

ID=39126775

Family Applications (2)

Application Number Title Priority Date Filing Date
DK12162958.8T DK2484696T3 (da) 2006-08-28 2007-08-24 Antagonistiske hLIGHT-specifikke humane monoklonale antistoffer
DK10172151.2T DK2292663T3 (da) 2006-08-28 2007-08-24 Antagonistiske human-let-specifikke, humane monoklonale antistoffer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK10172151.2T DK2292663T3 (da) 2006-08-28 2007-08-24 Antagonistiske human-let-specifikke, humane monoklonale antistoffer

Country Status (30)

Country Link
US (4) US8058402B2 (da)
EP (3) EP2064243A2 (da)
JP (2) JP5209625B2 (da)
KR (2) KR101314362B1 (da)
AU (1) AU2007290570C1 (da)
BR (1) BRPI0716088B8 (da)
CA (1) CA2661782C (da)
CO (1) CO6170363A2 (da)
CR (1) CR10652A (da)
CY (1) CY1114719T1 (da)
DK (2) DK2484696T3 (da)
EA (1) EA021255B1 (da)
ES (2) ES2643687T3 (da)
GT (1) GT200900043A (da)
HK (1) HK1153209A1 (da)
HR (1) HRP20131215T1 (da)
IL (2) IL197158A (da)
MA (1) MA31347B1 (da)
MX (1) MX2009002151A (da)
MY (1) MY162024A (da)
NI (1) NI200900027A (da)
NO (1) NO20091235L (da)
NZ (2) NZ575163A (da)
PL (1) PL2292663T3 (da)
PT (1) PT2292663E (da)
RS (1) RS53120B (da)
SG (1) SG170032A1 (da)
TN (1) TN2009000051A1 (da)
TW (2) TW201343676A (da)
WO (1) WO2008027338A2 (da)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ605429A (en) 2002-09-06 2014-08-29 Amgen Inc Therapeutic human anti-il-1r1 monoclonal antibody
ES2643687T3 (es) * 2006-08-28 2017-11-23 Kyowa Hakko Kirin Co., Ltd. Anticuerpos monoclonales humanos específicos de hLIGHT antagonistas
WO2009039310A2 (en) * 2007-09-18 2009-03-26 La Jolla Institute For Allergy And Immunology Light inhibitors for asthma, lung and airway inflammation, respiratory, interstitial, pulmonary and fibrotic disease treatment
US9700606B2 (en) * 2008-07-08 2017-07-11 La Jolla Institute For Allergy And Immunology HVEM/BTLA, HVEM/CD 160 and HVEM/gD cis complexes and methods of use
KR20170091801A (ko) 2008-10-02 2017-08-09 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Ｃｄ86 길항제 다중-표적 결합 단백질
CN102428103B (zh) * 2009-03-24 2015-04-08 泰华生物制药美国公司 抗light的人源化抗体及其使用
EP2780360B1 (en) * 2011-11-15 2023-03-08 Sanford Burnham Prebys Medical Discovery Institute Compositions and methods for treating autoimmune and inflammatory disorders
ES2702246T3 (es) * 2012-03-26 2019-02-28 Sanofi Sa Formulaciones de agente de unión IgG4 estables
CA3123252C (en) 2012-03-26 2023-08-22 Sanofi Stable anti-cxcr5 igg4 antibody formulations
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
US20130315913A1 (en) 2012-03-26 2013-11-28 Sanofi Anti-light antibody therapy for inflammatory bowel disease
JP6153019B2 (ja) 2013-01-31 2017-06-28 国立大学法人 東京大学 リゾホスファチジルセリン受容体機能調節活性を有する化合物
EP3094651B1 (en) * 2014-01-14 2020-03-11 Kymab Limited Anti-light antibodies
GB201403775D0 (en) 2014-03-04 2014-04-16 Kymab Ltd Antibodies, uses & methods
TWI555513B (zh) * 2014-05-27 2016-11-01 奇美醫療財團法人奇美醫院 管體窄化監測裝置及其監測方法
JP6369721B2 (ja) 2014-07-04 2018-08-08 国立大学法人 東京大学 リゾホスファチジルセリン誘導体
MA41414A (fr) * 2015-01-28 2017-12-05 Centre Nat Rech Scient Protéines de liaison agonistes d' icos
EP3730188B1 (en) * 2015-08-21 2024-07-31 The Children's Hospital of Philadelphia Compositions and methods for use in combination for the treatment and diagnosis of autoimmune diseases
US11779604B2 (en) 2016-11-03 2023-10-10 Kymab Limited Antibodies, combinations comprising antibodies, biomarkers, uses and methods
CA3045296A1 (en) 2016-12-07 2018-06-14 Progenity, Inc. Gastrointestinal tract detection methods, devices and systems
AU2017378393B2 (en) 2016-12-14 2023-03-09 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a TNF inhibitor
GB201701194D0 (en) 2017-01-24 2017-03-08 Capella Bioscience Ltd Antigen binding molecules that bind light
US11312781B2 (en) 2018-01-24 2022-04-26 Capella Bioscience Ltd. Antigen binding molecules that bind LIGHT
EP3810095A1 (en) 2018-06-20 2021-04-28 Progenity, Inc. Treatment of a disease of the gastrointestinal tract with a tnf inhibitor
WO2020106757A1 (en) 2018-11-19 2020-05-28 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
EP4056232A4 (en) 2019-09-13 2023-09-13 Kyowa Kirin Co., Ltd. DCR3 VARIANT
WO2021102173A1 (en) * 2019-11-21 2021-05-27 Unity Biotechnology Antibodies directed to tie-2 and methods of use
WO2021119482A1 (en) 2019-12-13 2021-06-17 Progenity, Inc. Ingestible device for delivery of therapeutic agent to the gastrointestinal tract
US11708406B2 (en) * 2020-04-01 2023-07-25 Avalo Therapeutics, Inc. Method of treating acute respiratory distress syndrome (ARDS) or acute lung injury (ALI) associate with COVID-19 by administering an anti-LIGHT antibody
AU2023205910A1 (en) * 2022-01-05 2024-06-06 Avalo Therapeutics, Inc. Methods of treating asthma with anti-light antibodies
WO2024067344A1 (zh) * 2022-09-27 2024-04-04 舒泰神（北京）生物制药股份有限公司 特异性识别light的抗体及其应用

Family Cites Families (246)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US452281A (en) 1891-05-12 Railway signaling device
US627366A (en) 1899-06-20 John treleaven
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US3710795A (en) 1970-09-29 1973-01-16 Alza Corp Drug-delivery device with stretched, rate-controlling membrane
GB1429184A (en) 1972-04-20 1976-03-24 Allen & Hanburys Ltd Physically anti-inflammatory steroids for use in aerosols
US4044126A (en) 1972-04-20 1977-08-23 Allen & Hanburys Limited Steroidal aerosol compositions and process for the preparation thereof
USRE28819E (en) 1972-12-08 1976-05-18 Syntex (U.S.A.) Inc. Dialkylated glycol compositions and medicament preparations containing same
US4444887A (en) 1979-12-10 1984-04-24 Sloan-Kettering Institute Process for making human antibody producing B-lymphocytes
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4358603A (en) 1981-04-16 1982-11-09 Syntex (U.S.A.) Inc. Acetal stabilized prostaglandin compositions
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
EP0092918B1 (en) 1982-04-22 1988-10-19 Imperial Chemical Industries Plc Continuous release formulations
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
US4716111A (en) 1982-08-11 1987-12-29 Trustees Of Boston University Process for producing human antibodies
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US5128326A (en) 1984-12-06 1992-07-07 Biomatrix, Inc. Drug delivery systems based on hyaluronans derivatives thereof and their salts and methods of producing same
WO1986005807A1 (en) 1985-04-01 1986-10-09 Celltech Limited Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same
US4980286A (en) 1985-07-05 1990-12-25 Whitehead Institute For Biomedical Research In vivo introduction and expression of foreign genetic material in epithelial cells
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
DE3883899T3 (de) 1987-03-18 1999-04-22 Sb2, Inc., Danville, Calif. Geänderte antikörper.
US4880078A (en) 1987-06-29 1989-11-14 Honda Giken Kogyo Kabushiki Kaisha Exhaust muffler
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
US5336603A (en) 1987-10-02 1994-08-09 Genentech, Inc. CD4 adheson variants
DE68921982D1 (de) 1988-06-14 1995-05-04 Cetus Oncology Corp Kupplungsmittel und sterisch gehinderte, mit disulfid gebundene konjugate daraus.
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE768377T1 (de) 1988-09-02 1998-01-02 Dyax Corp Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen
KR900005995A (ko) 1988-10-31 1990-05-07 우메모또 요시마사 변형 인터류킨-2 및 그의 제조방법
US5734033A (en) 1988-12-22 1998-03-31 The Trustees Of The University Of Pennsylvania Antisense oligonucleotides inhibiting human bcl-2 gene expression
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
EP0394827A1 (en) 1989-04-26 1990-10-31 F. Hoffmann-La Roche Ag Chimaeric CD4-immunoglobulin polypeptides
ZA902949B (en) 1989-05-05 1992-02-26 Res Dev Foundation A novel antibody delivery system for biological response modifiers
US5112946A (en) 1989-07-06 1992-05-12 Repligen Corporation Modified pf4 compositions and methods of use
US5413923A (en) 1989-07-25 1995-05-09 Cell Genesys, Inc. Homologous recombination for universal donor cells and chimeric mammalian hosts
US5436146A (en) 1989-09-07 1995-07-25 The Trustees Of Princeton University Helper-free stocks of recombinant adeno-associated virus vectors
WO1991005548A1 (en) 1989-10-10 1991-05-02 Pitman-Moore, Inc. Sustained release composition for macromolecular proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
WO1991006570A1 (en) 1989-10-25 1991-05-16 The University Of Melbourne HYBRID Fc RECEPTOR MOLECULES
AU642932B2 (en) 1989-11-06 1993-11-04 Alkermes Controlled Therapeutics, Inc. Protein microspheres and methods of using them
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5585112A (en) 1989-12-22 1996-12-17 Imarx Pharmaceutical Corp. Method of preparing gas and gaseous precursor-filled microspheres
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5314995A (en) 1990-01-22 1994-05-24 Oncogen Therapeutic interleukin-2-antibody based fusion proteins
JP3319594B2 (ja) 1990-03-20 2002-09-03 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 定常領域の代わりに受容体結合性リガンドを有するキメラ抗体
IT1246382B (it) 1990-04-17 1994-11-18 Eurand Int Metodo per la cessione mirata e controllata di farmaci nell'intestino e particolarmente nel colon
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5349053A (en) 1990-06-01 1994-09-20 Protein Design Labs, Inc. Chimeric ligand/immunoglobulin molecules and their uses
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
KR100272077B1 (ko) 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
AU660629B2 (en) 1990-10-01 1995-07-06 University Of Connecticut, The Targeting viruses and cells for selective internalization by cells
US5543390A (en) 1990-11-01 1996-08-06 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University Covalent microparticle-drug conjugates for biological targeting
DK0574395T3 (da) 1990-11-09 2002-10-07 Stephen D Gillies Cytokin-immunkonjugater
ATE164395T1 (de) 1990-12-03 1998-04-15 Genentech Inc Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DK0517895T3 (da) 1990-12-14 1997-04-07 Univ California Kimæriske kæder til receptorforbundne signaltransduktionsveje
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
JPH06507404A (ja) 1991-05-01 1994-08-25 ヘンリー　エム．ジャクソン　ファウンデイション　フォー　ザ　アドバンスメント　オブ　ミリタリー　メディスン 感染性の呼吸性疾患の治療方法
DE69231736T2 (de) 1991-05-14 2001-10-25 The Immune Response Corp., Carlsbad Gerichtete abgabe von genen, die immunogene proteine kodieren
DE69233482T2 (de) 1991-05-17 2006-01-12 Merck & Co., Inc. Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen
AU2160992A (en) 1991-06-05 1993-01-12 Board Of Regents Acting For And On Behalf Of The University Of Michigan, The Targeted delivery of genes encoding secretory proteins
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
US5844095A (en) 1991-06-27 1998-12-01 Bristol-Myers Squibb Company CTLA4 Ig fusion proteins
ES2136092T3 (es) 1991-09-23 1999-11-16 Medical Res Council Procedimientos para la produccion de anticuerpos humanizados.
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
US5824307A (en) 1991-12-23 1998-10-20 Medimmune, Inc. Human-murine chimeric antibodies against respiratory syncytial virus
WO1993014188A1 (en) 1992-01-17 1993-07-22 The Regents Of The University Of Michigan Targeted virus
US5622929A (en) 1992-01-23 1997-04-22 Bristol-Myers Squibb Company Thioether conjugates
US6271242B1 (en) 1992-02-10 2001-08-07 Bristol-Myers Squibb Co. Method for treating cancer using a tyrosine protein kinase inhibitor
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US5912015A (en) 1992-03-12 1999-06-15 Alkermes Controlled Therapeutics, Inc. Modulated release from biocompatible polymers
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
US6010715A (en) 1992-04-01 2000-01-04 Bertek, Inc. Transdermal patch incorporating a polymer film incorporated with an active agent
US5447851B1 (en) 1992-04-02 1999-07-06 Univ Texas System Board Of Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells
CA2133411A1 (en) 1992-04-03 1993-10-14 Alexander T. YOUNG Gene therapy using targeted viral vectors
US6024975A (en) 1992-04-08 2000-02-15 Americare International Diagnostics, Inc. Method of transdermally administering high molecular weight drugs with a polymer skin enhancer
DK0656946T4 (da) 1992-08-21 2010-07-26 Univ Bruxelles Immunoglobuliner uden lette kæder
US6005079A (en) 1992-08-21 1999-12-21 Vrije Universiteit Brussels Immunoglobulins devoid of light chains
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
DE69330167T2 (de) 1992-10-09 2001-11-15 Advanced Tissue Sciences, Inc. Leberreservezellen
EP0911413A3 (en) 1992-12-03 2000-11-15 Genzyme Corporation Minimal adenovirus-based gene therapy vector
US5441050A (en) 1992-12-18 1995-08-15 Neoprobe Corporation Radiation responsive surgical instrument
US5934272A (en) 1993-01-29 1999-08-10 Aradigm Corporation Device and method of creating aerosolized mist of respiratory drug
US6274552B1 (en) 1993-03-18 2001-08-14 Cytimmune Sciences, Inc. Composition and method for delivery of biologically-active factors
US5523092A (en) 1993-04-14 1996-06-04 Emory University Device for local drug delivery and methods for using the same
US5985307A (en) 1993-04-14 1999-11-16 Emory University Device and method for non-occlusive localized drug delivery
DK0698097T3 (da) 1993-04-29 2001-10-08 Unilever Nv Produktion af antistoffer eller (funktionaliserede) fragmenter deraf afledt af Camelidae-immunoglobuliner med tung kæde
AU691820B2 (en) 1993-07-15 1998-05-28 Cancer Research Campaign Technology Limited Prodrugs of protein tyrosine kinase inhibitors
US6004534A (en) 1993-07-23 1999-12-21 Massachusetts Institute Of Technology Targeted polymerized liposomes for improved drug delivery
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
US5925376C1 (en) 1994-01-10 2001-03-20 Madalene C Y Heng Method for treating psoriasis using selected phosphorylase kinase inhibitor and additional compounds
US5618709A (en) 1994-01-14 1997-04-08 University Of Pennsylvania Antisense oligonucleotides specific for STK-1 and method for inhibiting expression of the STK-1 protein
PT744958E (pt) 1994-01-31 2003-11-28 Univ Boston Bancos de anticorpos policlonais
US5834252A (en) 1995-04-18 1998-11-10 Glaxo Group Limited End-complementary polymerase reaction
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
US5837458A (en) 1994-02-17 1998-11-17 Maxygen, Inc. Methods and compositions for cellular and metabolic engineering
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
AU3382595A (en) 1994-07-29 1996-03-04 Smithkline Beecham Corporation Novel compounds
GB9415379D0 (en) 1994-07-29 1994-09-21 Smithkline Beecham Plc Novel compounds
US5759542A (en) 1994-08-05 1998-06-02 New England Deaconess Hospital Corporation Compositions and methods for the delivery of drugs by platelets for the treatment of cardiovascular and other diseases
US5911995A (en) 1994-08-19 1999-06-15 Regents Of The University Of Minnesota EGF-genistein conjugates for the treatment of cancer
US5587459A (en) 1994-08-19 1996-12-24 Regents Of The University Of Minnesota Immunoconjugates comprising tyrosine kinase inhibitors
US5660854A (en) 1994-11-28 1997-08-26 Haynes; Duncan H Drug releasing surgical implant or dressing material
WO1996020698A2 (en) 1995-01-05 1996-07-11 The Board Of Regents Acting For And On Behalf Of The University Of Michigan Surface-modified nanoparticles and method of making and using same
DE69636312T2 (de) 1995-01-17 2007-06-06 The Brigham And Women's Hospital Inc., Boston Rezeptorspezifischer Transepithelealer Transport von Immunogenen
US6030613A (en) 1995-01-17 2000-02-29 The Brigham And Women's Hospital, Inc. Receptor specific transepithelial transport of therapeutics
GB9501567D0 (en) 1995-01-26 1995-03-15 Pharmacia Spa Hydrosoluble 3-arylidene-2-oxindole derivatives as tyrosine kinase inhibitors
US5998596A (en) 1995-04-04 1999-12-07 The United States Of America As Represented By The Department Of Health And Human Services Inhibition of protein kinase activity by aptameric action of oligonucleotides
US6019968A (en) 1995-04-14 2000-02-01 Inhale Therapeutic Systems, Inc. Dispersible antibody compositions and methods for their preparation and use
US5983134A (en) 1995-04-23 1999-11-09 Electromagnetic Bracing Systems Inc. Electrophoretic cuff apparatus drug delivery system
EP1978033A3 (en) 1995-04-27 2008-12-24 Amgen Fremont Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP0841068B1 (en) 1995-06-01 2006-07-12 Kishimoto, Tadamitsu Leukemic cell growth inhibitor containing antisense oligonucleotide derivative against wilms' tumor gene (wt1)
US6316652B1 (en) 1995-06-06 2001-11-13 Kosta Steliou Drug mitochondrial targeting agents
GB9515975D0 (en) 1995-08-04 1995-10-04 Zeneca Ltd Chemical compounds
US6167301A (en) 1995-08-29 2000-12-26 Flower; Ronald J. Iontophoretic drug delivery device having high-efficiency DC-to-DC energy conversion circuit
CA2230494A1 (en) 1995-08-31 1997-03-06 Alkermes Controlled Therapeutics Inc. Composition for sustained release of an agent
US5863904A (en) 1995-09-26 1999-01-26 The University Of Michigan Methods for treating cancers and restenosis with P21
GB9601081D0 (en) 1995-10-06 1996-03-20 Cambridge Antibody Tech Specific binding members for human transforming growth factor beta;materials and methods
US6039975A (en) 1995-10-17 2000-03-21 Hoffman-La Roche Inc. Colon targeted delivery system
US6001358A (en) 1995-11-07 1999-12-14 Idec Pharmaceuticals Corporation Humanized antibodies to human gp39, compositions containing thereof
US6127366A (en) 1995-11-22 2000-10-03 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
DE69620445T2 (de) 1995-12-08 2002-12-12 Janssen Pharmaceutica N.V., Beerse (imidazol-5-yl)methyl-2-chinolinoderivate als farnesyl protein transferase inhibitoren
US5723125A (en) 1995-12-28 1998-03-03 Tanox Biosystems, Inc. Hybrid with interferon-alpha and an immunoglobulin Fc linked through a non-immunogenic peptide
US5958769A (en) 1996-01-18 1999-09-28 Fred Hutchinson Cancer Research Center Compositions and methods for mediating cell cycle progression
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
US6066738A (en) 1996-01-30 2000-05-23 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2000504017A (ja) 1996-01-30 2000-04-04 メルク エンド カンパニー インコーポレーテッド ファルネシル―タンパク質転移酵素の阻害剤
ATE508733T1 (de) 1996-03-04 2011-05-15 Penn State Res Found Materialien und verfahren zur steigerung der zellulären internalisierung
WO1997033899A1 (en) 1996-03-14 1997-09-18 Human Genome Sciences, Inc. Apoptosis inducing molecule i
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
US7964190B2 (en) 1996-03-22 2011-06-21 Human Genome Sciences, Inc. Methods and compositions for decreasing T-cell activity
KR100497017B1 (ko) 1996-03-22 2005-11-29 휴먼 게놈 사이언시즈, 인코포레이티드 고사유도분자ii
US6495520B2 (en) 1996-03-22 2002-12-17 Human Genome Sciences, Inc. Apoptosis Inducing Molecule II and methods of use
US6479254B2 (en) 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
US6635743B1 (en) 1996-03-22 2003-10-21 Human Genome Sciences, Inc. Apoptosis inducing molecule II and methods of use
US5883105A (en) 1996-04-03 1999-03-16 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6080870A (en) 1996-04-03 2000-06-27 Merck & Co., Inc. Biaryl substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
US5891889A (en) 1996-04-03 1999-04-06 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6063930A (en) 1996-04-03 2000-05-16 Merck & Co., Inc. Substituted imidazole compounds useful as farnesyl-protein transferase inhibitors
DE19617461A1 (de) 1996-05-02 1997-11-06 Bayer Ag Acylmercapto-triazolyl-Derivate
US6300501B1 (en) 1996-05-22 2001-10-09 Warner-Lambert Company Histidine-(N-benzyl glycinamide) inhibitors of protein farnesyl transferase
US5985309A (en) 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5855913A (en) 1997-01-16 1999-01-05 Massachusetts Instite Of Technology Particles incorporating surfactants for pulmonary drug delivery
US5874064A (en) 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
TW345603B (en) 1996-05-29 1998-11-21 Gmundner Fertigteile Gmbh A noise control device for tracks
US5648239A (en) 1996-06-21 1997-07-15 Incyte Pharmaceuticals, Inc. Human camp-dependent protein kinase inhibitor homolog
US6071935A (en) 1996-06-27 2000-06-06 Pfizer Inc. Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use as farnesyl protein transferase inhibitors
DE69730607T2 (de) 1996-07-19 2005-01-27 Takeda Chemical Industries, Ltd. Fas ligand ähnliches protein, seine herstellung und verwendung
IL128456A0 (en) 1996-08-12 2000-01-31 Yoshitomi Pharmaceutical Compositions containing a Rho kinase inhibitor
US5985317A (en) 1996-09-06 1999-11-16 Theratech, Inc. Pressure sensitive adhesive matrix patches for transdermal delivery of salts of pharmaceutical agents
US5945429A (en) 1996-09-13 1999-08-31 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6040305A (en) 1996-09-13 2000-03-21 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6030982A (en) 1996-09-13 2000-02-29 Schering Corporationm Compounds useful for inhibition of farnesyl protein transferase
US5885834A (en) 1996-09-30 1999-03-23 Epstein; Paul M. Antisense oligodeoxynucleotide against phosphodiesterase
US6139865A (en) 1996-10-01 2000-10-31 Eurand America, Inc. Taste-masked microcapsule compositions and methods of manufacture
US5916771A (en) 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6131570A (en) 1998-06-30 2000-10-17 Aradigm Corporation Temperature controlling device for aerosol drug delivery
ATE549918T1 (de) 1996-12-03 2012-04-15 Amgen Fremont Inc Menschliche antikörper, die ausdrücklich menschliches tnf alpha binden
US5939439A (en) 1996-12-30 1999-08-17 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6093737A (en) 1996-12-30 2000-07-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6013662A (en) 1996-12-30 2000-01-11 Rhone-Poulenc Rorer S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
WO1998031346A1 (en) 1997-01-16 1998-07-23 Massachusetts Institute Of Technology Preparation of particles for inhalation
US6414145B1 (en) 1997-01-29 2002-07-02 Zeneca Limited Imidazolyl compounds as inhibitors of farnesyl-protein tranferase
US5860957A (en) 1997-02-07 1999-01-19 Sarcos, Inc. Multipathway electronically-controlled drug delivery system
ZA981080B (en) 1997-02-11 1998-08-12 Warner Lambert Co Bicyclic inhibitors of protein farnesyl transferase
TW591030B (en) 1997-03-10 2004-06-11 Janssen Pharmaceutica Nv Farnesyl transferase inhibiting 1,8-annelated quinolinone derivatives substituted with N- or C-linked imidazoles
US6120751A (en) 1997-03-21 2000-09-19 Imarx Pharmaceutical Corp. Charged lipids and uses for the same
CZ294425B6 (cs) 1997-04-14 2005-01-12 Micromet Ag Způsob výroby anti-humánního antigenového receptoru, anti-humánní antigenový receptor, řetězec VH a VL, souprava pro selekci anti-humánních antigenových receptorů a farmaceutická kompozice, obsahující uvedený receptor
US6060082A (en) 1997-04-18 2000-05-09 Massachusetts Institute Of Technology Polymerized liposomes targeted to M cells and useful for oral or mucosal drug delivery
US6235883B1 (en) 1997-05-05 2001-05-22 Abgenix, Inc. Human monoclonal antibodies to epidermal growth factor receptor
US6239140B1 (en) 1997-06-17 2001-05-29 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6051582A (en) 1997-06-17 2000-04-18 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6225322B1 (en) 1997-06-17 2001-05-01 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6228865B1 (en) 1997-06-17 2001-05-08 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6159984A (en) 1997-06-17 2000-12-12 Schering Corporation Farnesyl protein transferase inhibitors
US6211193B1 (en) 1997-06-17 2001-04-03 Schering Corporation Compounds useful for inhibition of farnesyl protein transferase
US6140467A (en) 1997-07-07 2000-10-31 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6998108B1 (en) 1997-07-07 2006-02-14 La Jolla Institute For Allergy And Immunology Antibodies to p30 polypeptides and methods making and using same
US7118742B2 (en) 1997-07-07 2006-10-10 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
US6346388B1 (en) 1997-08-13 2002-02-12 Smithkline Beecham Corporation Method of identifying agonist and antagonists for tumor necrosis related receptors TR1 and TR2
UA61970C2 (en) 1997-08-15 2003-12-15 Combined use of tyrosine kinase inhibitor and a chemical castration agent for treating prostate cancer
US5948433A (en) 1997-08-21 1999-09-07 Bertek, Inc. Transdermal patch
US5989463A (en) 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6103723A (en) 1997-10-17 2000-08-15 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
JP2001524455A (ja) 1997-10-22 2001-12-04 アストラゼネカ ユーケイ リミテッド イミダゾール誘導体およびファルネシルタンパク質トランスフェラーゼインヒビターとしてのそれらの使用
AU9452998A (en) 1997-10-22 1999-05-10 Zeneca Limited Imidazole derivatives and their use as farnesyl protein transferase inhibit ors
SE512663C2 (sv) 1997-10-23 2000-04-17 Biogram Ab Inkapslingsförfarande för aktiv substans i en bionedbrytbar polymer
KR100719273B1 (ko) 1997-10-28 2007-05-18 반도 카가쿠 가부시키가이샤 피부 패치 시트 및 그것을 위한 베이스 시트의 제조 방법
CA2309541C (en) 1997-11-03 2011-01-11 Human Genome Sciences, Inc. Vegi, an inhibitor of angiogenesis and tumor growth
US6124465A (en) 1997-11-25 2000-09-26 Rhone-Poulenc S.A. Farnesyl transferase inhibitors, their preparation, the pharmaceutical compositions which contain them and their use in the preparation of medicaments
US6268363B1 (en) 1997-11-28 2001-07-31 Lg Chemical Ltd. Imidazole derivatives having an inhibitory activity for farnesyl transferase and process for preparation thereof
US6054466A (en) 1997-12-04 2000-04-25 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US6242196B1 (en) 1997-12-11 2001-06-05 Dana-Farber Cancer Institute Methods and pharmaceutical compositions for inhibiting tumor cell growth
US6335156B1 (en) 1997-12-18 2002-01-01 The Johns Hopkins University School Of Medicine 14-3-3σ arrests the cell cycle
ES2185307T3 (es) 1998-02-02 2003-04-16 Lg Chemical Ltd Inhibidores de la farnesil transferasa que tienen una estructura piperidinica y procedimiento para su preparacion.
EP1054968A1 (en) 1998-02-20 2000-11-29 Human Genome Sciences, Inc. Apoptosis inducing molecule ii and methods of use
WO1999055725A1 (en) 1998-04-27 1999-11-04 Warner-Lambert Company Functionalized alkyl and alkenyl side chain derivatives of glycinamides as farnesyl transferase inhibitors
US6048736A (en) 1998-04-29 2000-04-11 Kosak; Kenneth M. Cyclodextrin polymers for carrying and releasing drugs
JP2002518432A (ja) 1998-06-24 2002-06-25 アドバンスト インハレーション リサーチ，インコーポレイテッド 吸入器から放出される大多孔性粒子
SI1094815T1 (en) 1998-07-06 2004-04-30 Janssen Pharmaceutica N.V. Farnesyl protein transferase inhibitors for treating arthropathies
US6034053A (en) 1998-07-13 2000-03-07 Wayne Hughes Institute EGF-isoflavone conjugates for the prevention of restenosis
US6362188B1 (en) 1998-12-18 2002-03-26 Schering Corporation Farnesyl protein transferase inhibitors
US6372747B1 (en) 1998-12-18 2002-04-16 Schering Corporation Farnesyl protein transferase inhibitors
FR2787327B1 (fr) 1998-12-21 2003-01-17 Aventis Pharma Sa Compositions contenant des inhibiteurs de farnesyle transferase
US6432959B1 (en) 1998-12-23 2002-08-13 Schering Corporation Inhibitors of farnesyl-protein transferase
AU779008C (en) 1999-01-11 2005-06-30 Princeton University High affinity inhibitors for target validation and uses thereof
US6399633B1 (en) 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
US6245759B1 (en) 1999-03-11 2001-06-12 Merck & Co., Inc. Tyrosine kinase inhibitors
US6271359B1 (en) 1999-04-14 2001-08-07 Musc Foundation For Research Development Tissue-specific and pathogen-specific toxic agents and ribozymes
US6143766A (en) 1999-04-16 2000-11-07 Warner-Lambert Company Benzopyranone and quinolone inhibitors of ras farnesyl transferase
CA2374273A1 (en) 1999-05-21 2000-11-30 Takeda Chemical Industries, Ltd. Liver function controlling agents
US6256533B1 (en) 1999-06-09 2001-07-03 The Procter & Gamble Company Apparatus and method for using an intracutaneous microneedle array
US6458935B1 (en) 1999-06-23 2002-10-01 Merck & Co., Inc. Radiolabeled farnesyl-protein transferase inhibitors
EP1233987B1 (en) 1999-11-29 2009-08-19 Bac Ip B.V. Immobilized single domain antigen-binding molecules
US6403581B1 (en) 2000-01-19 2002-06-11 American Cyanamid Company Method of inhibition of farnesyl-protein transferase using substituted benz (cd) indol-2-imine and-amine derivatives
US6261595B1 (en) 2000-02-29 2001-07-17 Zars, Inc. Transdermal drug patch with attached pocket for controlled heating device
WO2001079496A2 (en) 2000-03-13 2001-10-25 La Jolla Institute For Allergy And Immunology Ligand for herpes simplex virus entry mediator and methods of use
PL366062A1 (en) 2000-09-08 2005-01-24 Micromet Ag Antibody and/or chemokine constructs and their use in immunological disorders
DE60131456T2 (de) * 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
EP1364653A4 (en) 2001-02-23 2005-01-26 Takeda Pharmaceutical CASOASE-3 INHIBITORS
EP1970448A1 (en) 2001-05-11 2008-09-17 Kirin Pharma Kabushiki Kaisha Human artificial chromosome containting human antibody lambda light chain and non-human animal containting the human artificial chromosome capable of genetic transmission
WO2003002127A1 (en) 2001-06-29 2003-01-09 Glykos Finland Oy Use of at least one glycoinhibitor substance
WO2003040307A2 (en) 2001-07-27 2003-05-15 Human Genome Sciences, Inc. Heteromultimeric tnf ligand family members
AR035119A1 (es) * 2001-08-16 2004-04-14 Lilly Co Eli Anticuerpos humanos antagonistas anti-htnfsf13b
EP1336619A3 (en) 2002-02-19 2003-12-10 Millenium Pharmaceuticals, Inc. Combination of a HVEM-LIGHT inhibitor and an immunosuppressive agent in the treatment or prevention of immune disorders
CA2481401A1 (en) 2002-04-15 2003-10-30 Human Genome Sciences, Inc. Antibodies that specifically bind to tl5
US20060008861A1 (en) 2002-04-15 2006-01-12 Allnutt F C T Incorporation of anaerobic bacteria in feed formulation
AU2004280333A1 (en) 2003-08-22 2005-04-21 Medimmune, Llc Humanization of antibodies
US20090311280A1 (en) 2004-12-09 2009-12-17 La Jolla Institute For Allergy And Immunology Novel tnf receptor regulatory domain
ES2643687T3 (es) * 2006-08-28 2017-11-23 Kyowa Hakko Kirin Co., Ltd. Anticuerpos monoclonales humanos específicos de hLIGHT antagonistas

Also Published As

Publication number Publication date
RS53120B (en) 2014-06-30
EA021255B1 (ru) 2015-05-29
HRP20131215T1 (hr) 2014-01-31
US20150337046A1 (en) 2015-11-26
TW201343676A (zh) 2013-11-01
EP2484696A1 (en) 2012-08-08
BRPI0716088A8 (pt) 2020-03-31
EP2484696B1 (en) 2017-08-16
TW200825104A (en) 2008-06-16
US9771419B2 (en) 2017-09-26
WO2008027338A2 (en) 2008-03-06
BRPI0716088B8 (pt) 2021-05-25
CA2661782A1 (en) 2008-03-06
US20100021466A1 (en) 2010-01-28
KR101374983B1 (ko) 2014-03-17
MX2009002151A (es) 2009-07-03
AU2007290570C1 (en) 2013-08-15
US8974787B2 (en) 2015-03-10
TWI405771B (zh) 2013-08-21
SG170032A1 (en) 2011-04-29
IL197158A0 (en) 2011-08-01
KR101314362B1 (ko) 2013-10-10
NZ596091A (en) 2012-07-27
JP5209625B2 (ja) 2013-06-12
DK2292663T3 (da) 2013-11-04
JP5751680B2 (ja) 2015-07-22
EP2292663A3 (en) 2011-11-23
US8461307B2 (en) 2013-06-11
CA2661782C (en) 2019-04-16
EP2292663A2 (en) 2011-03-09
GT200900043A (es) 2010-04-29
PL2292663T3 (pl) 2014-03-31
KR20130064814A (ko) 2013-06-18
CR10652A (es) 2009-05-13
CO6170363A2 (es) 2010-06-18
CY1114719T1 (el) 2016-10-05
ES2439994T3 (es) 2014-01-27
JP2013153749A (ja) 2013-08-15
JP2010502183A (ja) 2010-01-28
MA31347B1 (fr) 2010-05-03
TN2009000051A1 (en) 2010-08-19
ES2643687T3 (es) 2017-11-23
IL197158A (en) 2014-09-30
AU2007290570B2 (en) 2013-01-10
NZ575163A (en) 2011-12-22
EA200970234A1 (ru) 2010-02-26
AU2007290570A1 (en) 2008-03-06
NI200900027A (es) 2011-10-25
US20130230536A1 (en) 2013-09-05
EP2064243A2 (en) 2009-06-03
EP2292663B1 (en) 2013-10-02
US8058402B2 (en) 2011-11-15
BRPI0716088B1 (pt) 2020-12-08
MY162024A (en) 2017-05-31
US20120076798A1 (en) 2012-03-29
AU2007290570A2 (en) 2010-09-09
BRPI0716088A2 (pt) 2013-10-01
IL216381A0 (en) 2011-12-29
KR20090057285A (ko) 2009-06-04
PT2292663E (pt) 2013-11-04
WO2008027338A3 (en) 2008-07-24
NO20091235L (no) 2009-04-29
HK1153209A1 (en) 2012-03-23

Similar Documents

Publication Publication Date Title
DK2484696T3 (da) Antagonistiske hLIGHT-specifikke humane monoklonale antistoffer
KR20100033523A (ko) Ｐａｒ－２에 결합하는 항원 결합 단백질
US10259880B2 (en) Anti-LIGHT antibodies
US20220017627A1 (en) Antibodies against il-7r alpha subunit and uses thereof
CN101663321B (zh) 拮抗型人light特异性人源性单克隆抗体
AU2013203359B2 (en) Antagonistic human LIGHT-specific human monoclonal antibodies